Company: PTHS
Filing Date: 2025-09-16
Form Type: 8-K/A
Source: 0001753926-25-001500
Chunk: 152

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-09-16
Form: 8-K/A
Chunk 152
---
 $50.1 million in July 2025 related to the Merger, we expect that costs associated with the commercial launch of ZELSUVMI, in addition to other activities, will require us to raise additional funds. However, there is no assurance that we will be able to raise such additional funds on acceptable terms, if at all. If we raise additional funds by issuing securities, existing stockholders may be diluted.

In addition, we may utilize our available financial resources sooner than we currently expect. We will need to raise additional capital in the future if we decide to expand our business to develop other product candidates, or to pursue strategic investments or acquisitions, and we may consider raising additional capital to take advantage of favorable market conditions or financing opportunities or for other reasons.

Our future capital requirements will depend on many factors, including, but not limited to:

| ● | The                                                                                                        
 level of sales achieved from the commercialization of ZELSUVMI for the treatment of molluscum contagiosum; |

| ● | the                                                                                          
 costs of commercializing ZELSUVMI, including our business development and marketing efforts; |

| ● | the                                                         
 effect of competing products and other market developments; |

| ● | the                                                                     
 extent to which we acquire or seek to develop other product candidates; |

| ● | the                                                                                                                            
 costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents and other intellectual property 
 and proprietary rights, and                                                                                                    |

| ● | our                                                                                                                  
 efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company. |

We anticipate that our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures and other general corporate purposes.

Cash Flow Summary

| (Dollars in thousands)          
 Net cash provided by (used in): 
 Operating activities            
 Investing activities            |     | Six months ended 
 June 30,         
 2025             | (15,664 
     (67 | ) 
 ) |     | 2024 | (12,678 
     (29 | ) 
 ) |
|:--------------------------------|:----|:-----------------|--------:|:--|:----|:-----|--------:|:--|
| Financing activities            |     |                  |  18,548 |   |     | $    |  12,707 |   |

Net cash used in operating activities for the six months ended June 30, 2025 and 2024